Email this article Tomudeks - novyy effektivnyy protivoopukholevyy preparat
- Authors: Lichinitser MR1
-
Affiliations:
- РОНЦ им. Н.Н. Блохина РАМН
- Issue: Vol 2, No 4 (2000)
- Pages: 126-131
- Section: Articles
- URL: https://journal-vniispk.ru/1815-1434/article/view/26384
- ID: 26384
Cite item
Full Text
Abstract
В последние годы большое внимание уделяется созданию новых антиметаболитов с высокой избирательностью и специфичностью противоопухолевого действия. Особый интерес вызывает томудекс , который является специфическим ингибитором тимидилат синтетазы (ТС), с которой ТС взаимодействует целая группа противоопухолевых препаратов (5-фторурацил, фторафур, UFT, капецитабин и др.). Однако только с помощью Томудекса достигается прямое блокирование ТС. Томудекс вызывает снижение фолатной транспортной системы в клеточной мембране опухолевой клетки, превращается в полиглютаматные формы и эффективно блокирует опухолевый рост.Томудекс является высокоэффективным противоопухолевым лекарством. Томудекс разрешен для применения в онкологической практике в России.
Full Text
##article.viewOnOriginalSite##References
- Blackledge G., et al. Neu1 dei 'elopments in cancer treatment with the not 'el thymidylate synthase inhibitor raltitrexed. Br J Cancer 1998; 77 (suppl 2): 29-37-
- Camaghi C, et al. Promising activity oflrinotecan and Tomudex as first line chemotherapy in metastatic colorectal cancer. Proceeding of ASCO, 2000; 307 a, N1211.
- Caponigro F., et al. Phase I and pharmacokinetic study of Tomudex + 5-Fluorouracil/levofolinic acid in adi >anced head and neck and colorectal cancer. Proc. ASCO, 1998; 17:237-
- Catalano G., et al. Oxaliplatin and Tomudex followed by Levo-Leucovorin modulated 5-Fluorouracil i.V. bolus every} 2 weeks. A dose finding study in advanced colorectal carcinoma. Proc. ASCO, 2000,p. 2 72 a, N 1062.
- Chang Y, et al. Prêtre atment of colon carcinoma cells to D1696 (Tomudex) markedly enchances 5-Fluorouracil toxity. Proc. Am Assoc Cancer res, 1994:35: A1966.
- Clarke S., et al. Phase I trial of ZD1694, a new folate - based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol, 1996; 14: 1495-1403.
- Cunninghdm D., et al. "Tomudex" (ZD 1694): a novel thymidylate synthase inhibitor with clinical antitumor activity in a range of solid tumors. Ann Oncol, I996; 7: 179-182.
- Cunningham D., et al. Final results of a randomized trial comparing "Tomudex" (raltitrexed) with 5'-Fluorouracilplus Leucovorin in advanced colorectal cancer. Ann Oncol, 1996; 7: 961-5-
- Cunningham D., et al. Mature results from 3 large controlled studies with Tomudex. Br J Cancer, 1998; 77 (suppl 2): 15-21.
- Douillard J., et al. Tomudex plus Oxaliplatin: an active combination for firstline chemotherapy in patients with metastatic colorectal cancer. Proc. ASCO, 2000;250a(971).
- Fizazi K. Et al. The combination Tomudex and Oxaliplatin is an active regimen in malignant mesothelioma. Proc. Of ASCO, 2000,p. 578a, N2276.
- Garcia M., et al. Biweekly Irinotecan combined with Tomudex treatment in heavily pretreated patients with advanced colorectal cancer. Proc. Of ASCO, 2000, p. 254a, N987.
- Harstrick A, et al. Combination therapy with infusional 5-FU and Tomudex for patients with advdnced colorectal cancer - a phase I study. Annals of Oncology, 1998; 9 (Suppl 4): 35.
- Judson L, et al. "Tomudex" (raltitrexed) development: preclinical, phase I and studies. Anti - cancer Drugs, 1997; 8 (suppl 2): 5-9-
- Kimbell R., et al. Combination studies with Tomudex and 5-Fluorouracil in human colon cancer cell lines. Br J Cancer 1996; 73:29-
- Lewis N. et al. Rhase I and pharmacokinetic study oflrinotecan in combination with Tomudex.Proc.ASCO, 2000,p. 195a,N 757-
- Lichinitser M., Dobrova N, Semenov N. Tomudex (T) and Tomudex + 5-Fluoruracil (T + 5-FU) for advanced colorectal cancer. Proc. of ASCO, 1999; 18: 1117.
- Mayer S., et al. Extended phase I study of Tomudex and infusional 5-FU in patients with metastatic colorectal cancer. Proc. ASCO, 2000,p. 299a, N1169.
- Pazdur R, et al. Raltitrexed (Tomudex) vs 5- Fluorouracil + Leucovorin (5-FU+LV) in patients with advanced colorectal cancer: results of a randomised multicenter North American trial. Proc Am Soc Clin Oncol, 1997; 16: 228.
- Scheithaner W., et al. Promising therapeutic potential of Oxaliplatin +Tomudex in patients with advanced colorectal cancer. Proc. Of ASCO, 2000, p. 257a, N997-
- Sorensenf., et al. Phase I trial of ZD 1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann Oncol, 1994; 5 (suppl 5): 132.
- Zalcberg J., et al. ZD 1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol, 1996; 14: 716-21.
- Zalcberg J., et al. Overview of the tolerability of "Tomudex" (ralitrexed): collective clinical experience in advanced colorectal cancer. Anticancer Drugs, 1997; 8 (suppl 2): 17-22.
Supplementary files
